When I spoke with my Strategic Tech Investor readers last week, I illustrated how one of our "Million-Dollar Tech Portfolio" stocks had soared 53% in just a little over two months.
But Repligen Corp. (Nasdaq: RGEN) isn't the only big winner. In fact, six of our seven investments in the Million-Dollar Tech Portfolio are up – and the other is just a hair below breakeven.
Repligen's gain was by far the largest – but one other stock is up 22.7% in the period, and another one rallied for profits of 17.9%.
It just proves what I said in that special report: "The road to wealth is paved by tech."
With that in mind, let's take a look at how our portfolio is already producing annualized gains of nearly 90%.
And then I'll show you why I still like these plays for the long haul…
Sextupling the Market
As I have said for some time now, if you want to make serious money in the stock market you have to be invested in high tech.
Of course, that doesn't mean you can just throw a dart at the Nasdaq Composite Index and expect to find a profitable play. You need someone in your corner who knows how to spot winners in the making… someone who's spent 35+ years analyzing and investing in Silicon Valley.
Consider this: Since March 6, when Strategic Tech Investor readers received "The Million-Dollar Tech Portfolio" report, the Standard & Poor's 500 Index was up 1.7% late last week.
Our average gain in the portfolio – 15.4% – was more than six times that amount.
If we extrapolate out our success so far, we're talking close to 90% gains for the year…
Not only that, but there's not a single loser in the bunch. With that in mind, let's take a look at each of our seven Million-Dollar investments.
Let's get started…
Million-Dollar Tech Portfolio Winner No. 1: Repligen Corp.
Repligen Corp. (Nasdaq: RGEN) had recently soared more than 17% in a single session. For a time that day, it was the tenth-biggest gainer among all stocks traded on major U.S. exchanges.
I said I still saw plenty of upside ahead, but that the stock might temporarily give back some of its recent gains. Well, I'm happy to report the opposite has happened – the stock has continued to gain.
That reinforces my belief that this key supplier to the biotech industry still has plenty of upside left. The stock opened Wednesday at $41.67 and has a market cap of $1.37 billion.
Million-Dollar Tech Portfolio Winner No. 2: Ambarella Inc.
I call this exciting small-cap player the "video everywhere" company. Ambarella Inc. (Nasdaq: AMBA) leads the world in advanced video-compression and image-processing technology.
That's why you'll find its devices being used by the leading wearable sports camera on the market today, the helmet-mounted HERO from GoPro Inc. (Nasdaq: GPRO).
Ambarella also makes devices used for automotive backup cameras. This is a market with huge upside because, beginning in July 2018, all cars and light-duty trucks in the United States must have backup cameras.
Plus, the Santa Clara, Calif.-based company makes processing technology for ultra-high-definition TV (UHDTV) broadcasts. Using 2013 as the base year, the Consumer Electronics Association projects a 60-fold sales increase for UHDTV through 2106, when it expects sales of 1.43 million units.
With a market cap of $2.63 billion, Ambarella stock was trading at $85.95 yesterday afternoon. The company recently beat on sales and earnings for its fiscal fourth quarter. I'm still projecting the stock will double from my original estimate in as little as 3.2 years. Year to date alone it's up 69%!
Million-Dollar Tech Portfolio Winner No. 3: CoreLogic Inc.
This is a great double play on two powerful long-term trends. The first is Big Data – when computers crunch through massive amounts of unstructured information to find profitable trends.
Second, CoreLogic Inc. (NYSE: CLGX) focuses on the burgeoning market for online real estate shopping. A recent analysis by the National Association of Realtors found that 74% of potential buyers intended to use the Web to search for a house.
Based in Irvine, Calif., CoreLogic operates deep databases on several real estate sectors, covering everything from single-family homes to natural gas pipelines.
The company also sifts through data to provide background checks on prospective clients. It can even determine whether someone has a criminal conviction for property damage.
Opening at $39.94 yesterday, the stock has a market cap of $3.62 billion. The stock got a boost after CoreLogic beat on first-quarter earnings. I projected stock gains of 26% through March 2016, and we're well on our way.
Million-Dollar Tech Portfolio Winner No. 4: First Trust IPOX-100 Index Fund
Strictly speaking, the First Trust IPOX-100 Index Fund (NYSE: FPX) is not a pure technology play. Instead, it captures the upside that initial public offerings (IPOs) can provide – but without all the volatility.
As such, FPX attempts to invest in the 100 recent largest, best-performing U.S. IPOs – and about 40% of its stocks are in high-tech or tech-centric healthcare firms. Its two biggest holdings are social-media leader Facebook Inc. (Nasdaq: FB) and biopharmaceutical giant AbbVie Inc. (Nasdaq: ABBV).
So, this is an exchange-traded fund (ETF) that both rides the tech boom and gives us plenty of diversification. Its other holdings cover autos, retail, finance, energy, and heavy industry.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.